Series B financing will support Exciva's Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's disease (AD) Financing was co-led by EQT Life Sciences out of its LSP Dementia Fund, together with Gimv, with participation from Fountain Healthcare...
Hence then, the article about eqt life sciences co leads eur 51 million series b in exciva to advance its alzheimer s therapy into clinical phase 2 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer's therapy into clinical Phase 2 )
Also on site :
- Russia-Ukraine war: List of key events, day 1,426
- Rangers’ Cody Bradford Targeting Return In May From Elbow Surgery
- '90s Trash Metal Band Releases New Single Ahead of Farewell Album